Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE3
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE2
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2